[go: up one dir, main page]

ECSP10010032A - derivados de azaciclilisoquinolinona e -isoindolinona como antagonistas de la HISTAMINA-3 - Google Patents

derivados de azaciclilisoquinolinona e -isoindolinona como antagonistas de la HISTAMINA-3

Info

Publication number
ECSP10010032A
ECSP10010032A EC2010010032A ECSP10010032A ECSP10010032A EC SP10010032 A ECSP10010032 A EC SP10010032A EC 2010010032 A EC2010010032 A EC 2010010032A EC SP10010032 A ECSP10010032 A EC SP10010032A EC SP10010032 A ECSP10010032 A EC SP10010032A
Authority
EC
Ecuador
Prior art keywords
histamine
azacyclylisoquinolinone
antagonists
isoindolinone derivatives
isoindolinone
Prior art date
Application number
EC2010010032A
Other languages
English (en)
Inventor
Dahui Zhou
Albert Jean Robichaud
Jonathan Laird Gross
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of ECSP10010032A publication Critical patent/ECSP10010032A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

RESUMEN DE LA INVENCIÓN La presente invención proporciona un compuesto de fórmula I y su uso para el tratamiento de un trastorno del sistema nervioso central relacionado con, o que se ve afectado por, el receptor de la histamina-3.
EC2010010032A 2007-09-12 2010-03-12 derivados de azaciclilisoquinolinona e -isoindolinona como antagonistas de la HISTAMINA-3 ECSP10010032A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99355407P 2007-09-12 2007-09-12

Publications (1)

Publication Number Publication Date
ECSP10010032A true ECSP10010032A (es) 2010-08-31

Family

ID=40261508

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010032A ECSP10010032A (es) 2007-09-12 2010-03-12 derivados de azaciclilisoquinolinona e -isoindolinona como antagonistas de la HISTAMINA-3

Country Status (23)

Country Link
US (1) US20090069370A1 (es)
EP (1) EP2200998A1 (es)
JP (1) JP2010539178A (es)
KR (1) KR20100054852A (es)
CN (1) CN101842366A (es)
AP (1) AP2010005199A0 (es)
AU (1) AU2008298983A1 (es)
BR (1) BRPI0816806A2 (es)
CA (1) CA2699383A1 (es)
CL (1) CL2008002708A1 (es)
CO (1) CO6300951A2 (es)
CR (1) CR11309A (es)
DO (1) DOP2010000078A (es)
EA (1) EA201000319A1 (es)
EC (1) ECSP10010032A (es)
MA (1) MA31700B1 (es)
MX (1) MX2010002899A (es)
NI (1) NI201000035A (es)
PA (1) PA8795601A1 (es)
PE (1) PE20090679A1 (es)
TN (1) TN2010000107A1 (es)
TW (1) TW200918062A (es)
WO (1) WO2009036117A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
JP2011213700A (ja) * 2010-04-02 2011-10-27 Nishizaki Soyaku Kenkyusho:Kk 認知症改善用組成物
WO2011143150A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
AR081383A1 (es) 2010-05-11 2012-08-29 Sanofi Aventis N-heteroaril bipirrolidin carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades del sistema nervioso central.
JP5766278B2 (ja) 2010-05-11 2015-08-19 サノフイ 置換されたｎ−アルキルおよびｎ−アシルテトラヒドロ−イソキノリン誘導体、それらの製造および治療上の使用
TW201206910A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
JP5784110B2 (ja) 2010-05-11 2015-09-24 サノフイ 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用
TW201202251A (en) 2010-05-11 2012-01-16 Sanofi Aventis Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
EP2535062A1 (en) 2011-06-13 2012-12-19 Dentsply IH AB Collagen coated article
US9295531B2 (en) 2011-06-13 2016-03-29 Dentsply International Inc. Collagen coated article
PT2785695T (pt) * 2011-11-30 2020-08-20 Hoffmann La Roche Novos derivados bicíclicos de dihidroisoquinolina-1-ona
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
LT3063139T (lt) 2013-10-29 2019-02-25 Takeda Pharmaceutical Company Limited Heterociklinis junginys
CN112209876B (zh) * 2020-10-15 2022-08-26 华侨大学 一种3-三氟甲基异喹啉酮衍生物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
SE7907121L (sv) * 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
AU4319797A (en) * 1996-09-25 1998-04-17 Yamanouchi Pharmaceutical Co., Ltd. 2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinoline derivatives or medicinal compositions thereof
WO1998048800A1 (en) * 1997-05-01 1998-11-05 Eli Lilly And Company Antithrombotic agents
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US7572784B2 (en) * 2004-05-14 2009-08-11 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
SE0401970D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
MX2007008843A (es) * 2005-01-21 2007-08-22 Schering Corp Derivados de imidazol y bencimidazol utiles como antagonistas de histamina h3.
US20070032475A1 (en) * 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
US8143284B2 (en) * 2006-10-05 2012-03-27 Abbott Laboratories Poly(ADP-ribose)polymerase inhibitors
US7799806B2 (en) * 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators

Also Published As

Publication number Publication date
MX2010002899A (es) 2010-04-09
NI201000035A (es) 2010-07-15
BRPI0816806A2 (pt) 2015-03-10
CL2008002708A1 (es) 2008-10-10
PE20090679A1 (es) 2009-05-28
DOP2010000078A (es) 2010-04-15
CO6300951A2 (es) 2011-07-21
TN2010000107A1 (fr) 2011-09-26
CA2699383A1 (en) 2009-03-19
PA8795601A1 (es) 2009-05-15
EA201000319A1 (ru) 2010-10-29
TW200918062A (en) 2009-05-01
JP2010539178A (ja) 2010-12-16
MA31700B1 (fr) 2010-09-01
WO2009036117A1 (en) 2009-03-19
EP2200998A1 (en) 2010-06-30
AP2010005199A0 (en) 2010-04-30
AU2008298983A1 (en) 2009-03-19
KR20100054852A (ko) 2010-05-25
CR11309A (es) 2010-04-07
US20090069370A1 (en) 2009-03-12
CN101842366A (zh) 2010-09-22

Similar Documents

Publication Publication Date Title
CO6300955A2 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina -3
ECSP10010032A (es) derivados de azaciclilisoquinolinona e -isoindolinona como antagonistas de la HISTAMINA-3
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
UY33379A (es) Compuestos de morfolina
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
CL2007001670A1 (es) Uso de compuestos derivados de amina para el tratamiento de un trastorno mediado por citoquinas.
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
BRPI0907382B8 (pt) antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
PA8790101A1 (es) Derivados de aminoalquilazol como antagonistas de histamina-3
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CO6260091A2 (es) Derivados de iminopiridina y su uso
HN2010002558A (es) DERIVADOS DE UREA MACROCICLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa
PA8781601A1 (es) " derivados de azaciclilbenzamida como antagonistas de histamina-3
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
BR112016012552A8 (pt) derivado de cromona como um antagonista do receptor d3 de dopamina, seu uso e sua composição farmacêutica
PA8814801A1 (es) Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos
ECSP088930A (es) Derivados de benzoxazol y benzotiazol como ligandos de
ECSP088789A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6
CU20100047A7 (es) Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3
CU20100045A7 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3